Publikationen, an denen er mitarbeitet María José Calasanz Abinzano (66)

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

2015

  1. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

    Haematologica

2014

  1. Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels

    Journal of Hematology and Oncology, Vol. 7, Núm. 1

2013

  1. Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells

    Haematologica

  2. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription

    Oncogene, Vol. 32, Núm. 16, pp. 2069-2078

2012

  1. Integration of SNP and mRNA Arrays with MicroRNA Profiling Reveals That MiR-370 Is Upregulated and Targets NF1 in Acute Myeloid Leukemia

    PLoS ONE, Vol. 7, Núm. 10

  2. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics

    PLoS ONE, Vol. 7, Núm. 8

  3. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities

    Leukemia

  4. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

    Haematologica, Vol. 97, Núm. 4, pp. 543-550

2011

  1. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

    Haematologica, Vol. 96, Núm. 10, pp. 1448-1456

  2. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect

    Leukemia, Vol. 25, Núm. 4, pp. 606-614

2010

  1. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2

    British Journal of Cancer, Vol. 103, Núm. 8, pp. 1292-1296

  2. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

    Blood, Vol. 115, Núm. 3, pp. 615-625

  3. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia

    Proceedings of the National Academy of Sciences of the United States of America

2009

  1. A novel t(7;13)(p12;q33∼q34) in AML-M2

    Cancer Genetics and Cytogenetics

2008

  1. A new dic(7;12)(p12.21;p12.2) chromosome aberration in a case of acute myeloid leukemia

    Cancer Genetics and Cytogenetics, Vol. 185, Núm. 2, pp. 102-105

2007

  1. DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups

    Leukemia, Vol. 21, Núm. 6, pp. 1224-1231

  2. Erratum: JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers (Leukemia (2007) vol. 21 (2386-2390) 10.1038/sj.leu.2404812)

    Leukemia

  3. JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers [15]

    Leukemia

  4. Multicolor interphase cytogenetics for the study of plasma cell dyscrasias

    Oncology Reports, Vol. 18, Núm. 5, pp. 1099-1106